Related Experiment Video
Updated: May 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Approach to the treatment-naïve patient with HCV genotype 1 infection
1Division of Gastroenterology, Duke Clinical Research Institute, Duke University School of Medicine, Room 0311 Terrace Level 2400 Pratt Street, Durham, NC 27715, USA. andrew.muir@duke.edu
Abstract:
In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial improvements in sustained virologic response rates, especially for treatment-naïve patients. This article reviews the approach to therapy with these genotype 1 treatment-naïve patients.
Related Concept Videos
Viral Hepatitis I: Introduction
Hepatitis
Retrovirus Life Cycles
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

